Naloxone Auto-Injector 10mg Logo

News

Featured In

August 2023 | JPEO-CBRND

DOD-Supported Lifesaving Autoinjector to Combat Ultra-Potent Opioid Exposure Available through DLA
September 2022 | Globe Newswire

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
September 2022 | Health.Mil

MHSRS 2022 Award Winner Video: Rapid Opioid Countermeasure System
September 2022 | JPEO-CBRND

Rapid Opioid Countermeasure System Product Team Wins 2022 Military Health System Research Symposium Award for Outstanding Program Management Team
May 2022 | JPEO-CBRND

DOD-Supported 10mg Naloxone Autoinjector Receives FDA Approval to Treat Known or Potential Ultra-Potent Opioid Exposure
April 2022 | HDIAC

DoD-Supported 10-mg Naloxone Autoinjector Receives FDA Approval to Treat Known or Potential Ultra-Potent Opioid Exposure
March 2022 | Pharmacy Times

FDA Approves 10-mg Naloxone Injection to Treat Exposure to Ultra-Potent Weaponized Opioids
March 2022 | EMPR.COM

FDA Approves Naloxone Auto-Injector as Countermeasure to High Potency Opioids
June 2021 | JBSA News

Army Medical Test and Evaluation Activity tests Rapid Opioid Countermeasure System at JBSA-Camp Bullis
June 2021 | army.mil

USAMTEAC Test Rapid Opioid Countermeasure System at Camp Bullis

INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION

Naloxone Auto-Injector 10 mg is an opioid antagonist indicated for use by military personnel and chemical incident responders for:

  • Temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids such as fentanyl analogues.
  • Emergency treatment of patients 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon is suspected.

IMPORTANT SAFETY INFORMATION

Contraindications, Warnings, Precautions, and Adverse Events

  • NAI 10 mg is contraindicated in individuals with hypersensitivity to naloxone hydrochloride or to any of the other ingredients in NAI 10 mg.
  • Use in patients who are opioid dependent may cause abrupt opioid withdrawal. Use of a product that delivers a dose lower than 10 mg of naloxone HCl may be preferable in treatment of a patient with known opioid dependence.
  • Due to the duration of action of naloxone HCl relative to the opioid, keep the patient under continued surveillance and administer additional naloxone HCl, as necessary, while awaiting emergency medical assistance.
  • The following adverse reactions were observed in more than one subject in clinical studies evaluating NAI: dizziness, feeling hot, headache, and injection site erythema.

Please see full Prescribing Information.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or fda.gov/medwatch.